drugset / Trial / NCT04739618
Metastatic Solid Cancer Clinical Trial
NaSingle-groupOpen-labelTreatment
Summary
This study seeks to estimate the potential efficacy of the study treatment, as well as the occurrence of adverse events.
Timeline
- Start
- 2021-03-04
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GM-CSF | Protein / enzyme biologic | 250 ug | Other |
| Subject | Ipilimumab | Monoclonal antibody | — | Other |
| Subject | Pembrolizumab | Monoclonal antibody | — | Other |